Comment
doi: 10.1158/1078-0432.CCR-09-2936.
Epub 2010 Jan 12.
Individualizing dosing of irinotecan
Affiliations
- PMID: 20068075
- DOI: 10.1158/1078-0432.CCR-09-2936
Item in Clipboard
Comment
Individualizing dosing of irinotecan
Clin Cancer Res.
.
Abstract
Individualized drug dosing is a longstanding goal of clinical pharmacologists. Given the narrow therapeutic index of most anticancer agents, it is plausible that this approach would be of particular value in oncology. Irinotecan is an interesting agent for individualized dosing, given its complex metabolism and increasing knowledge of its pharmacokinetics predictors.
Comment on
-
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.Clin Cancer Res. 2010 Jan 15;16(2):736-42. doi: 10.1158/1078-0432.CCR-09-1526. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068078 Clinical Trial.
Similar articles
-
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.Clin Cancer Res. 2010 Jan 15;16(2):736-42. doi: 10.1158/1078-0432.CCR-09-1526. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068078 Clinical Trial.
-
Irinotecan in the adjuvant treatment of colon cancer: is the story finished or does personalized therapy open new opportunities?J Clin Oncol. 2010 Apr 20;28(12):e199. doi: 10.1200/JCO.2009.25.8558. Epub 2010 Mar 22. J Clin Oncol. 2010. PMID: 20308659 No abstract available.
-
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.Clin Cancer Res. 2005 Feb 15;11(4):1504-11. doi: 10.1158/1078-0432.CCR-04-1758. Clin Cancer Res. 2005. PMID: 15746053 Clinical Trial.
-
Clinical and pharmacogenetic factors associated with irinotecan toxicity.Cancer Treat Rev. 2008 Nov;34(7):656-69. doi: 10.1016/j.ctrv.2008.05.002. Epub 2008 Jun 16. Cancer Treat Rev. 2008. PMID: 18558463 Review.
-
[Topoisomerase I inhibitor (irinotecan hydrochloride)].Nihon Rinsho. 2004 Dec;62 Suppl 12:456-60. Nihon Rinsho. 2004. PMID: 15658362 Review. Japanese. No abstract available.
Cited by
-
All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide.JCO Oncol Pract. 2022 Apr;18(4):270-277. doi: 10.1200/OP.21.00624. Epub 2021 Dec 3. JCO Oncol Pract. 2022. PMID: 34860573 Free PMC article.
-
Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients.J Clin Lab Anal. 2018 Jan;32(1):e22217. doi: 10.1002/jcla.22217. Epub 2017 Apr 10. J Clin Lab Anal. 2018. PMID: 28393405 Free PMC article.
-
Irinotecan pharmacogenomics.Pharmacogenomics. 2010 Jul;11(7):1003-10. doi: 10.2217/pgs.10.95. Pharmacogenomics. 2010. PMID: 20602618 Free PMC article. Review.
-
Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.Int J Clin Oncol. 2014 Apr;19(2):397-402. doi: 10.1007/s10147-013-0558-1. Epub 2013 Apr 19. Int J Clin Oncol. 2014. PMID: 23605141
-
Sequential designs for individualized dosing in phase I cancer clinical trials.Contemp Clin Trials. 2017 Dec;63:51-58. doi: 10.1016/j.cct.2016.08.018. Epub 2016 Aug 31. Contemp Clin Trials. 2017. PMID: 27592121 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
